Arketamine for bipolar depression: Open-label, dose-escalation, pilot study

• DOI: 10.1016/j.jpsychires.2023.06.028
• Publication Date: 2023-06-24T15:12:44Z
• Authors: Igor D. Bandeira; Gustavo C. Leal; Fernanda S. Corre...; Breno Souza-Marques; Samantha S. Silva; Daniel H. Lins-Silva; Rodrigo P. Mello; Flávia Vieira; Ingrid Dorea-Band...; Daniela Faria-Gui...; Beatriz Carneiro; Ana Teresa Calima...; Flávio Kapczinski; Ângela Miranda-Sc...; Acioly L.T. Lacerda; Lucas C. Quarantini
• Keywords: Depression; Bipolar II disorder; Major depressive episode; Treatment-Resistant Depression

There are significantly fewer options for the treatment of bipolar depression than major depressive disorder, with an urgent need for alternative therapies. In this pilot study, we treated six subjects with bipolar disorder types I and II (according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria) who had been in a current depressive episode for at least four weeks. Four subjects were female (66.66%), and the mean age was 45.33 (±12.32). Subjects received adjunct treatment with two arketamine intravenous infusions one week apart-0.5 mg/kg first and then 1 mg/kg. The mean baseline Montgomery-Åsberg Depression Rating Scale (MADRS) total score was 36.66, which decreased to 27.83 24h after the first infusion of 0.5 mg/kg of arketamine (p = 0.036). In respect of the 1 mg/kg dose, the mean MADRS total score before the second infusion was 32.0, which dropped to 17.66 after 24h (p < 0.001). Arketamine appears to have rapid-acting antidepressant properties, consistent with previous animal studies on major depression. All individuals tolerated both doses, exhibiting nearly absent dissociation, and no manic symptoms. To the best of our knowledge, this pilot trial is the first to test the feasibility and safety of the (R)-enantiomer of ketamine (arketamine) for bipolar depression.